{"id":"il-2-interleukin-2","safety":{"commonSideEffects":[{"rate":null,"effect":"Capillary leak syndrome"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Chills"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Thrombocytopenia"},{"rate":null,"effect":"Oliguria/acute kidney injury"}]},"_chembl":{"chemblId":"CHEMBL1201438","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Interleukin-2 is a cytokine that acts as a growth factor for lymphocytes, particularly CD8+ cytotoxic T cells and natural killer cells. By engaging the high-affinity IL-2 receptor complex, it drives T cell expansion and activation, enhancing their ability to recognize and eliminate cancer cells. IL-2 also promotes the generation of memory T cells, contributing to durable anti-tumor immunity.","oneSentence":"IL-2 binds to IL-2 receptors on T cells and NK cells, promoting their proliferation, activation, and differentiation to enhance anti-tumor immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:48:05.701Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic renal cell carcinoma"},{"name":"Metastatic melanoma"}]},"trialDetails":[{"nctId":"NCT01038778","phase":"PHASE1, PHASE2","title":"Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2009-10-29","conditions":"Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7","enrollment":47},{"nctId":"NCT06767046","phase":"PHASE1","title":"KRAS-Specific Autologous TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Corregene Biotechnology Co., Ltd","startDate":"2025-02-18","conditions":"Colorectal, Pancreatic, Non-small Cell Lung Cancer (NSCLC)","enrollment":8},{"nctId":"NCT02557074","phase":"PHASE3","title":"TREg Activation in the Treatment of the PELADE (Alopecia Areata)","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2015-12-15","conditions":"Alopecia Areata","enrollment":44},{"nctId":"NCT06730126","phase":"PHASE2","title":"Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-03-10","conditions":"Autoimmune Lymphoproliferative Syndrome","enrollment":15},{"nctId":"NCT00338377","phase":"PHASE2","title":"Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2006-02-01","conditions":"Melanoma","enrollment":1230},{"nctId":"NCT06743126","phase":"PHASE3","title":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-01-14","conditions":"Melanoma, Cutaneous Malignant","enrollment":360},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":"Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia","enrollment":54},{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT06991361","phase":"PHASE1","title":"Ex Vivo-Expanded Regulatory T Cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic GVHD","status":"NOT_YET_RECRUITING","sponsor":"Leslie Kean","startDate":"2026-05-01","conditions":"Graft Versus Host Disease (cGvHD)","enrollment":21},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT04977453","phase":"PHASE1, PHASE2","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","status":"RECRUITING","sponsor":"GI Innovation, Inc.","startDate":"2021-08-02","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Cervical Cancer","enrollment":317},{"nctId":"NCT04347616","phase":"PHASE1, PHASE2","title":"Natural Killer-cell Therapy for Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Radboud University Medical Center","startDate":"2020-12-03","conditions":"Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, Relapsed, Adult","enrollment":9},{"nctId":"NCT07217301","phase":"PHASE3","title":"IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed","status":"RECRUITING","sponsor":"Fortvita Biologics (USA)Inc.","startDate":"2025-11-26","conditions":"iO Resistant sqNSCLC","enrollment":600},{"nctId":"NCT02858310","phase":"PHASE1, PHASE2","title":"E7 TCR T Cells for Human Papillomavirus-Associated Cancers","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-27","conditions":"Papillomavirus Infections, Cervical Intraepithelial Neoplasia, Carcinoma In Situ","enrollment":224},{"nctId":"NCT04695327","phase":"PHASE1","title":"TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 Monotherapy","status":"COMPLETED","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2021-01-11","conditions":"Solid Tumor","enrollment":32},{"nctId":"NCT00026312","phase":"PHASE3","title":"Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2001-10-26","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Recurrent Neuroblastoma","enrollment":1449},{"nctId":"NCT05877599","phase":"PHASE1","title":"A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-07-12","conditions":"Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma","enrollment":46},{"nctId":"NCT06321484","phase":"PHASE1","title":"Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-10-09","conditions":"Platinum-resistant Ovarian Cancer, Recurrent Ovary Cancer, Ovarian Cancer","enrollment":18},{"nctId":"NCT07443020","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors","status":"NOT_YET_RECRUITING","sponsor":"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT04426669","phase":"PHASE1, PHASE2","title":"A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering","status":"COMPLETED","sponsor":"Intima Bioscience, Inc.","startDate":"2020-05-15","conditions":"Gastrointestinal Epithelial Cancer, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract","enrollment":23},{"nctId":"NCT05566223","phase":"PHASE1, PHASE2","title":"CISH Inactivated TILs in the Treatment of NSCLC","status":"WITHDRAWN","sponsor":"Intima Bioscience, Inc.","startDate":"2023-02","conditions":"Carcinoma, Non-Small-Cell Lung, Metastatic Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer","enrollment":""},{"nctId":"NCT02340676","phase":"PHASE2","title":"A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2015-02","conditions":"Chronic Graft-versus-host-disease","enrollment":25},{"nctId":"NCT04052334","phase":"PHASE1","title":"Lymphodepletion Plus Adoptive Cell Therapy With High Dose IL-2 in Adolescent and Young Adult Patients With Soft Tissue Sarcoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2019-09-27","conditions":"Sarcoma","enrollment":9},{"nctId":"NCT01366092","phase":"PHASE2","title":"Daily IL-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2011-07","conditions":"Chronic Graft-versus-host Disease","enrollment":35},{"nctId":"NCT01659151","phase":"PHASE2","title":"Vemurafenib With Lymphodepletion Plus Adoptive Cell Transfer & High Dose IL-2 Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-08-03","conditions":"Metastatic Melanoma","enrollment":17},{"nctId":"NCT07389239","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies.","status":"NOT_YET_RECRUITING","sponsor":"University of Chicago","startDate":"2026-06-23","conditions":"Ovarian Cancer, Advanced Malignant Solid Tumor","enrollment":24},{"nctId":"NCT07410494","phase":"PHASE1, PHASE2","title":"Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Essen Biotech","startDate":"2026-02-01","conditions":"Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC)","enrollment":85},{"nctId":"NCT06237881","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-01-31","conditions":"Advanced Solid Tumor, Melanoma, Lung Neoplasms","enrollment":15},{"nctId":"NCT07288073","phase":"PHASE2","title":"TIL Therapy in cSCC and MCC","status":"RECRUITING","sponsor":"Karam Khaddour, MD, MS","startDate":"2026-02-10","conditions":"Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma","enrollment":14},{"nctId":"NCT06158828","phase":"PHASE1, PHASE2","title":"Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2024-05-15","conditions":"AML, Childhood, Aml, Acute Myeloid Leukemia, Pediatric","enrollment":68},{"nctId":"NCT05493566","phase":"EARLY_PHASE1","title":"Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Emory University","startDate":"2022-11-01","conditions":"Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8","enrollment":15},{"nctId":"NCT06598371","phase":"PHASE1, PHASE2","title":"A Phase 1/2 Study of KSQ-004EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate Genes Encoding SOCS1 and Regnase-1, in Patients With Select Advanced Solid Tumors","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-11-21","conditions":"Select Advanced Solid Tumors","enrollment":141},{"nctId":"NCT05544448","phase":"NA","title":"In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-10-02","conditions":"Autoimmune Diseases, Inflammatory Disease, Acquired Bone Marrow Aplasia","enrollment":67},{"nctId":"NCT02964078","phase":"PHASE2","title":"Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2017-04-25","conditions":"Kidney Cancer","enrollment":27},{"nctId":"NCT03965468","phase":"PHASE2","title":"Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2019-11-19","conditions":"Non-small Cell Lung Cancer, Stage IV, Oligometastasis","enrollment":96},{"nctId":"NCT01937468","phase":"PHASE1","title":"Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for Steroid-Refractory Chronic Graft-versus-Host-Disease","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2013-11","conditions":"Chronic Graft Versus Host Disease, Chronic GVHD, Complications of Organ Transplant Stem Cells","enrollment":25},{"nctId":"NCT04263831","phase":"PHASE1, PHASE2","title":"Low Dose IL-2 for the Treatment of Crohn's Disease","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2021-03-11","conditions":"Crohn Disease","enrollment":30},{"nctId":"NCT03666000","phase":"PHASE1","title":"Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)","status":"RECRUITING","sponsor":"Imugene Limited","startDate":"2019-03-11","conditions":"Non-Hodgkin Lymphoma, B-cell Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia","enrollment":135},{"nctId":"NCT04562129","phase":"PHASE2","title":"IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2020-09-24","conditions":"Melanoma Stage III, Melanoma Stage IV, Inoperable Disease","enrollment":29},{"nctId":"NCT06318871","phase":"EARLY_PHASE1","title":"Memory-like Natural Killer (NK) Cell Therapy in Patients With Renal Cell Carcinoma or Urothelial Carcinoma","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-08-28","conditions":"Renal Carcinoma, Renal Cell Carcinoma, Urothelial Carcinoma","enrollment":10},{"nctId":"NCT03474497","phase":"PHASE1, PHASE2","title":"UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade","status":"ACTIVE_NOT_RECRUITING","sponsor":"Megan Daly, MD","startDate":"2019-05-20","conditions":"Non Small Cell Lung Cancer, Metastatic Melanoma, Metastatic Renal Cell Carcinoma","enrollment":18},{"nctId":"NCT05357027","phase":"PHASE1, PHASE2","title":"HPV16 E6 TCR T Cells for Cervical Carcinoma","status":"TERMINATED","sponsor":"TCRCure Biopharma Ltd.","startDate":"2022-08-10","conditions":"Cervical Carcinoma","enrollment":5},{"nctId":"NCT07192900","phase":"PHASE1","title":"Fast TILs to Treat Metastatic Cancer Patients With Pleural Disease","status":"RECRUITING","sponsor":"David Bartlett, MD","startDate":"2026-03","conditions":"Malignant Pleural Effusion, Malignant Mesothelioma, Pleural Effusion, Malignant","enrollment":10},{"nctId":"NCT02586831","phase":"PHASE1, PHASE2","title":"Diabetes Islet Preservation Immune Treatment","status":"WITHDRAWN","sponsor":"Camillo Ricordi and Jay Skyler","startDate":"2024-06-01","conditions":"Diabetes Mellitus, Type 1, Hypoglycemia, Autoimmune Diseases","enrollment":""},{"nctId":"NCT05989828","phase":"PHASE1","title":"A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"University of Southern California","startDate":"2024-12-17","conditions":"Triple Negative Breast Cancer","enrollment":20},{"nctId":"NCT02739412","phase":"PHASE2","title":"Efficacy of Low Dose, SubQ Interleukin-2 (IL-2) to Expand Endogenous Regulatory T-Cells in Liver Transplant Recipients","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2016-11","conditions":"Liver Transplantation","enrollment":6},{"nctId":"NCT06946225","phase":"PHASE1","title":"ACTengine® IMA203 Combined With mRNA-4203","status":"RECRUITING","sponsor":"Immatics US, Inc.","startDate":"2025-07-25","conditions":"Cutaneous Melanoma, Synovial Sarcoma","enrollment":15},{"nctId":"NCT06255028","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Century Therapeutics, Inc.","startDate":"2025-02-06","conditions":"Systemic Lupus Erythematosus, Lupus Nephritis, Idiopathic Inflammatory Myopathies","enrollment":6},{"nctId":"NCT05902520","phase":"PHASE1","title":"Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"AgonOx, Inc.","startDate":"2023-06-19","conditions":"HNSCC, Melanoma, Gynecologic Cancer","enrollment":18},{"nctId":"NCT06236425","phase":"PHASE1","title":"TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-03-14","conditions":"Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma","enrollment":7},{"nctId":"NCT05628883","phase":"PHASE1","title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-11-22","conditions":"Metastatic Melanoma, Unresectable Melanoma, Acral Melanoma","enrollment":17},{"nctId":"NCT06138587","phase":"PHASE1","title":"Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-01-24","conditions":"Acute Myeloid Leukemia, Leukemia, Leukemia, Myeloid","enrollment":15},{"nctId":"NCT07307053","phase":"PHASE1, PHASE2","title":"Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-01-01","conditions":"Rare Malignant Neoplasm, Advanced Solid Tumors, Metastatic Solid Tumors","enrollment":600},{"nctId":"NCT05307874","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study of ICT01 Plus Low Dose SC IL-2 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"ImCheck Therapeutics","startDate":"2022-05-04","conditions":"Solid Tumor, Adult","enrollment":56},{"nctId":"NCT06626256","phase":"PHASE1","title":"STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma","status":"WITHDRAWN","sponsor":"City of Hope Medical Center","startDate":"2025-12-05","conditions":"Locally Advanced Cervical Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Malignant Solid Neoplasm","enrollment":""},{"nctId":"NCT04155710","phase":"PHASE1","title":"Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL","status":"COMPLETED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2020-02-19","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":7},{"nctId":"NCT06125197","phase":"PHASE1","title":"Oncolytic Adenovirus TILT-123 With Pembrolizumab as Treatment for Refractory Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2024-07-23","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT01319565","phase":"PHASE2","title":"Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-03-24","conditions":"Metastatic Melanoma, Skin Cancer","enrollment":102},{"nctId":"NCT01701674","phase":"NA","title":"Ipilimumab With Lymphodepletion Plus Adoptive Cell Transfer and High Dose IL-2 in Melanoma Mets Pts","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2012-10-09","conditions":"Metastatic Melanoma","enrollment":13},{"nctId":"NCT05802056","phase":"PHASE1","title":"Aldesleukin With Nivolumab and Standard Chemotherapy for Treatment of Gastric Cancer With Peritoneal Metastasis","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2023-11-29","conditions":"Clinical Stage IV Gastric Cancer AJCC v8, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma","enrollment":15},{"nctId":"NCT01005745","phase":"NA","title":"Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2009-10-20","conditions":"Metastatic Melanoma","enrollment":19},{"nctId":"NCT05336409","phase":"PHASE1","title":"A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies","status":"TERMINATED","sponsor":"Century Therapeutics, Inc.","startDate":"2023-01-24","conditions":"R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma","enrollment":28},{"nctId":"NCT04009681","phase":"PHASE1, PHASE2","title":"A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)","status":"TERMINATED","sponsor":"Synthorx, Inc, a Sanofi company","startDate":"2019-06-20","conditions":"Metastasis","enrollment":175},{"nctId":"NCT03260504","phase":"PHASE1","title":"Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer","status":"TERMINATED","sponsor":"University of Washington","startDate":"2018-08-28","conditions":"Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer","enrollment":6},{"nctId":"NCT07255664","phase":"PHASE1, PHASE2","title":"A FIH, Phase I/IIa, Trial Assessing Feasibility of Administrations of TIL-based Immunotherapy in Patients With Metastatic CRC and PC","status":"RECRUITING","sponsor":"Curacell Holding AB","startDate":"2025-11-13","conditions":"Metastatic Colorectal Cancer, Prostate Cancer Metastatic, Prostate Cancer Locally Advanced","enrollment":12},{"nctId":"NCT05681780","phase":"PHASE1","title":"Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-03-10","conditions":"Non Small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT05768347","phase":"PHASE1","title":"Intravesical Adoptive Cell Therapy w/ TIL for BCG Exposed High Grade NMIBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2023-08-10","conditions":"Urothelial Carcinoma, Non-Invasive Bladder Urothelial Carcinoma","enrollment":9},{"nctId":"NCT03039673","phase":"PHASE2","title":"MIROCALS: Modifying Immune Response and OutComes in ALS","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2017-06-19","conditions":"Amyotrophic Lateral Sclerosis","enrollment":304},{"nctId":"NCT06961357","phase":"PHASE1, PHASE2","title":"Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-01-01","conditions":"Melanoma","enrollment":36},{"nctId":"NCT06940739","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel","status":"RECRUITING","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2025-03-11","conditions":"Unresectable Melanoma, Metastatic Melanoma, Ocular Melanoma","enrollment":42},{"nctId":"NCT05035407","phase":"PHASE1","title":"T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers","status":"TERMINATED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-08","conditions":"Kita-kyushu Lung Cancer Antigen 1, Human","enrollment":36},{"nctId":"NCT01697527","phase":"PHASE2","title":"Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jonsson Comprehensive Cancer Center","startDate":"2012-11-02","conditions":"Malignant Neoplasm","enrollment":6},{"nctId":"NCT03449108","phase":"PHASE2","title":"LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-04-27","conditions":"Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone","enrollment":30},{"nctId":"NCT06455917","phase":"PHASE2","title":"TIL Therapy in Non-small-cell Lung Cancer (NSCLC) Patients","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-01-22","conditions":"Non-Small Cell Lung Cancer, Lung Cancer (NSCLC)","enrollment":30},{"nctId":"NCT02059759","phase":"PHASE2","title":"Immuno-modulation in Amyotrophic Lateral Sclerosis- a Phase II Study of Safety and Activity of Low Dose Interleukin-2","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2015-09","conditions":"Amyotrophic Lateral Sclerosis","enrollment":36},{"nctId":"NCT01857934","phase":"PHASE2","title":"Therapy for Children With Advanced Stage Neuroblastoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2013-07-05","conditions":"Neuroblastoma","enrollment":153},{"nctId":"NCT05400122","phase":"PHASE1","title":"Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer","status":"SUSPENDED","sponsor":"David Wald","startDate":"2022-09-09","conditions":"Colorectal Cancer, Hematologic Malignancy, Rectum Cancer","enrollment":12},{"nctId":"NCT05194735","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors","status":"TERMINATED","sponsor":"Alaunos Therapeutics","startDate":"2022-04-04","conditions":"Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer","enrollment":8},{"nctId":"NCT02823990","phase":"PHASE2","title":"TG4010 and Nivolumab in Patients With Lung Cancer","status":"COMPLETED","sponsor":"Megan Daly, MD","startDate":"2016-12-14","conditions":"Recurrent Non-Small Cell Lung Carcinoma, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer","enrollment":13},{"nctId":"NCT07225439","phase":"PHASE1","title":"Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)","status":"NOT_YET_RECRUITING","sponsor":"Paolo Caimi, MD","startDate":"2025-12","conditions":"Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma","enrollment":15},{"nctId":"NCT05271318","phase":"PHASE1, PHASE2","title":"Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer.","status":"RECRUITING","sponsor":"TILT Biotherapeutics Ltd.","startDate":"2022-05-17","conditions":"Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma","enrollment":29},{"nctId":"NCT01590069","phase":"PHASE1","title":"Aerosolized Aldesleukin in Treating Patients With Lung Metastases","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-06-28","conditions":"Metastatic Malignant Neoplasm in the Lung, Metastatic Melanoma, Metastatic Osteosarcoma","enrollment":70},{"nctId":"NCT04409080","phase":"PHASE1","title":"REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy","status":"TERMINATED","sponsor":"Regeneron Pharmaceuticals","startDate":"2021-01-13","conditions":"Severe Aplastic Anemia (SAA)","enrollment":17},{"nctId":"NCT07049328","phase":"PHASE1","title":"HCW9302 (Interleukin-2 Fusion Protein) for Alopecia Areata","status":"RECRUITING","sponsor":"HCW Biologics","startDate":"2025-08-16","conditions":"Alopecia Areata(AA)","enrollment":30},{"nctId":"NCT01955460","phase":"PHASE1","title":"Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2014-10-15","conditions":"Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7","enrollment":34},{"nctId":"NCT07212933","phase":"PHASE2","title":"The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2025-07-01","conditions":"Gastric (Stomach) Cancer, Biological Therapy, Immunotherapy","enrollment":90},{"nctId":"NCT03782636","phase":"PHASE2","title":"Interleukin-2 Therapy of Autoimmunity in Diabetes (ITAD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Oxford","startDate":"2019-01-28","conditions":"Type1 Diabetes","enrollment":41},{"nctId":"NCT05296564","phase":"PHASE1, PHASE2","title":"Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers","status":"RECRUITING","sponsor":"Hadassah Medical Organization","startDate":"2022-04-01","conditions":"Sarcoma, Synovial, Sarcoma,Soft Tissue, Melanoma Stage IV","enrollment":3},{"nctId":"NCT06920199","phase":"EARLY_PHASE1","title":"Treatment of Refractory cGVHD by Donor-derived Treg Cell Injection Combined With Recombinant Human Interleukin-2","status":"RECRUITING","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2025-06-14","conditions":"cGVHD","enrollment":18},{"nctId":"NCT05385705","phase":"PHASE1","title":"A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020","status":"TERMINATED","sponsor":"Vall d'Hebron Institute of Oncology","startDate":"2022-05-11","conditions":"Breast Neoplasms","enrollment":2},{"nctId":"NCT04812470","phase":"PHASE1","title":"Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2023-02-06","conditions":"Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma","enrollment":8},{"nctId":"NCT07183852","phase":"PHASE1","title":"Locoregional or Systemic Administration of Autologous Tumor Infiltrating Lymphocytes in Patients With Metastatic Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Vastra Gotaland Region","startDate":"2026-03","conditions":"Metastatic Uveal Melanoma, Metastatic Cutaneous Melanoma","enrollment":18},{"nctId":"NCT05754684","phase":"PHASE2","title":"Quadruple Immunotherapy for Neuroblastoma","status":"RECRUITING","sponsor":"Hong Kong Children's Hospital","startDate":"2022-01-01","conditions":"Neuroblastoma Recurrent","enrollment":29},{"nctId":"NCT03970954","phase":"PHASE1, PHASE2","title":"Low-dose Interleukin-2 in Women With Unexplained Miscarriages","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-01-05","conditions":"Recurrent Miscarriage","enrollment":18},{"nctId":"NCT05653882","phase":"PHASE1","title":"A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Asher Biotherapeutics, Inc.","startDate":"2023-01-04","conditions":"Solid Tumor, Non Small Cell Lung Cancer, Melanoma","enrollment":552},{"nctId":"NCT05438667","phase":"EARLY_PHASE1","title":"TCR-T Cell Therapy on Advanced Solid Tumors","status":"RECRUITING","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2023-06-01","conditions":"Pancreatic Cancer","enrollment":18},{"nctId":"NCT06884670","phase":"PHASE2","title":"Assessment of Efficacy and Safety of PD-1 Monoclonal Antibody Combined With IL-2 and CapeOX in Neoadjuvant Therapy for Locally Advanced Rectal Cancer Prior to Surgery: A Prospective, Multi-center, Randomized Controlled Study","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-03-18","conditions":"Rectal Cancer","enrollment":130},{"nctId":"NCT05883449","phase":"PHASE2","title":"Phase 2 Study of AFM13 in Combination With AB-101 in Subjects With R/R HL and CD30+ PTCL","status":"TERMINATED","sponsor":"Affimed GmbH","startDate":"2023-10-10","conditions":"Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma","enrollment":25},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT02652455","phase":"EARLY_PHASE1","title":"Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma","status":"COMPLETED","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2016-03-08","conditions":"Melanoma (Skin), Skin Cancer","enrollment":11}],"_emaApprovals":[],"_faersSignals":[{"count":2,"reaction":"RASH"},{"count":1,"reaction":"BRADYCARDIA"},{"count":1,"reaction":"CORONARY ARTERY DISEASE"},{"count":1,"reaction":"DEEP VEIN THROMBOSIS"},{"count":1,"reaction":"FATIGUE"},{"count":1,"reaction":"HYPERTENSION"},{"count":1,"reaction":"HYPOAESTHESIA"},{"count":1,"reaction":"LIBIDO DECREASED"},{"count":1,"reaction":"MUSCULOSKELETAL STIFFNESS"},{"count":1,"reaction":"NAUSEA"}],"_approvalHistory":[],"publicationCount":111,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Proleukin"],"phase":"marketed","status":"active","brandName":"IL-2 (interleukin 2)","genericName":"IL-2 (interleukin 2)","companyName":"King's College London","companyId":"king-s-college-london","modality":"Small molecule","firstApprovalDate":"","aiSummary":"IL-2 binds to IL-2 receptors on T cells and NK cells, promoting their proliferation, activation, and differentiation to enhance anti-tumor and anti-viral immune responses. Used for Metastatic renal cell carcinoma, Metastatic melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}